2026-10-30 14:46:00 UTC#546403newconfirmednews
Incyte (INCY) stock news
Incyte (INCY) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-30 12:47:00 UTC#545655newconfirmednews
Evercore ISI Group maintains Incyte Corporation at In-Line rating
2026-10-30 09:37:00 UTC#544281duplicateconfirmednews
Oppenheimer upgrades Incyte to Outperform, raises price target to $144
2026-10-30 09:26:09 UTC#544222newconfirmednews
Oppenheimer upgrades Incyte to Outperform from Perform, raises price target to $144
2026-10-29 19:20:27 UTC#540099duplicateconfirmednews
Incyte updates 2026 Opzelura sales guidance to $1.10B-$1.12B, reaffirms total revenue outlook
2026-10-29 15:32:32 UTC#538673duplicateconfirmednews
Incyte reports Q3 revenue growth and reaffirms raised FY2026 sales guidance
2026-10-29 11:09:00 UTC#536497newconfirmedpress release
Incyte raises 2026 full-year revenue guidance to $5.21B-$5.3B
2026-10-29 11:08:00 UTC#536531newconfirmeddata release
Incyte reports Q3 Jakafi and Jakafi XR net sales of $827 million, up 4% year-over-year
2026-10-28 16:49:09 UTC#530650newforecastanalysis
Incyte Corporation Q3 2026 Earnings Preview
2026-10-26 18:14:13 UTC#516527newconfirmednews
Incyte reports positive clinical data for INCB161734 and INCA33890 in GI cancer programs
2026-10-24 11:01:00 UTC#510109newconfirmednews
Genmab and Incyte partner for Phase 1/2 trial of petosemtamab and INCB161734 in KRAS G12D-mutated mCRC
tradingviewimportance 0.40trust 0.70Genmab A/S +0.40Incyte Corporation +0.40petosemtamab +0.40+2 entities
2026-10-24 11:00:00 UTC#510115duplicateconfirmednews
Incyte and Genmab announce Phase 1/2 clinical trial collaboration for KRAS G12D-mutated mCRC
tradingviewimportance 0.30trust 0.80Incyte Corporation +0.30Genmab A/S +0.30INCB161734 +0.30+2 entities
2026-10-24 11:00:00 UTC#510114duplicateconfirmedpress release
Genmab and Incyte announce Phase 1/2 clinical trial collaboration for petosemtamab and INCB161734 in mCRC
globenewswireimportance 0.30trust 1.00Genmab A/S +0.30Incyte Corporation +0.30petosemtamab +0.30+1 entities
2026-10-24 11:00:00 UTC#510111duplicateconfirmednews
Genmab and Incyte to co-develop petosemtamab and INCB161734 in Phase 1/2 KRAS G12D mCRC trial
tradingviewimportance 0.30trust 0.60Genmab A/S +0.30Incyte Corporation +0.30petosemtamab +0.30+1 entities
2026-10-24 05:16:05 UTC#509706newconfirmednews
Incyte reports 48% ORR for INCB123667 plus bevacizumab in ovarian cancer, plans Phase 3 study for 2026
2026-10-21 14:57:31 UTC#493907newconfirmednews
TD Cowen maintains Buy rating on Incyte, sets $140 price target
2026-10-20 19:05:28 UTC#488505newconfirmednews
Prelude Therapeutics outlines KAT6A and JAK2 clinical timelines, eyes $100M Incyte option exercise
quartrimportance 0.40trust 0.60Prelude Therapeutics Inc. +0.30Incyte Corporation +0.40KAT6A +0.30+1 entities
2026-10-19 13:39:28 UTC#480886newconfirmedanalysis
Pharma sector accelerates AI adoption to cut R&D costs and timelines; industry reviews 2025-2026 partnerships
reutersimportance 0.40trust 0.80Pfizer Inc. +0.30PostEra, Inc. +0.30IQVIA Holdings Inc. +0.30+2 entities
2026-10-14 17:40:00 UTC#460806newconfirmednews
Truist Securities maintains Incyte at Hold, raises price target to $115 from $105
2026-10-13 10:36:52 UTC#451376newconfirmednews